外周作用的μ阿片受体拮抗剂预防复发性急性胰腺炎的效果:研究者发起的随机安慰剂对照双盲临床试验(PAMORA-RAP试验)研究方案
本研究为研究者发起的双盲随机安慰剂对照试验,拟从丹麦和瑞典五个专科中心纳入120例有复发性急性胰腺炎病史的门诊患者,随机分配至每日0.2 mg纳地美定组或匹配安慰剂组治疗12个月。主要终点为随机化后至急性胰腺炎复发的时间,次要结局包括生活质量、胃肠道症状评分、新发糖尿病、外分泌胰腺功能不全、疾病严重程度、医疗资源利用、治疗依从性和不良事件频率。
要点
- 纳入标准为有复发性急性胰腺炎病史(至少两次确诊胰腺炎发作)。
- 主要终点为随机化后至急性胰腺炎复发的时间。
- 探索性结局包括MRI上慢性胰腺炎相关表现的进展及循环炎症和纤维化标志物的变化。
核心结论
- 本研究探讨纳地美定能否改变复发性急性胰腺炎患者的胰腺炎自然病程并改善患者结局。
研究设计与样本
- 研究为双盲随机对照试验,患者随机分配至每日0.2 mg纳地美定组或匹配安慰剂组治疗12个月。
- 计划从丹麦和瑞典五个专科中心纳入120例门诊患者。
- 主要纳入标准为有复发性急性胰腺炎病史(至少两次确诊胰腺炎发作)。
关键数值与推荐
- 主要终点为随机化后至急性胰腺炎复发的时间。
- 次要结局包括生活质量变化、胃肠道症状评分、新发糖尿病、外分泌胰腺功能不全、疾病严重程度、医疗资源利用、治疗依从性和不良事件频率。
- 探索性结局包括MRI上慢性胰腺炎相关表现的进展及循环炎症和纤维化标志物的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute and chronic pancreatitis constitute a continuum of inflammatory disease of the pancreas with an increasing incidence in most high-income countries. A subset of patients with a history of pancreatitis suffer from recurrence of acute pancreatitis attacks, which accelerate disease progression towards end-stage chronic pancreatitis with loss of exocrine and endocrine function. There is currently no available prophylactic treatment for recurrent acute pancreatitis apart from removing risk factors, which is not always possible. Pain is the primary symptom of acute pancreatitis, which induces the endogenous release of opioids. This may further be potentiated by opioid administration for pain management. Increased exposure to opioids leads to potentially harmful effects on the gastrointestinal tract, including, e.g. increased sphincter tones and decreased fluid secretion, which may impair pancreatic ductal clearance and elevate the risk for new pancreatitis attacks and accelerate disease progression. Peripherally acting µ-opioid receptor antagonists (PAMORAs) have been developed to counteract the adverse effects of opioids on the gastrointestinal tract. We hypothesize that the PAMORA naldemedine will reduce the risk of new pancreatitis attacks in patients with recurrent acute pancreatitis and hence decelerate disease progression. METHODS: The study is a double-blind, randomized controlled trial with allocation of patients to either 0.2 mg naldemedine daily or matching placebo for 12 months. A total of 120 outpatients will be enrolled from five specialist centres in Denmark and Sweden. The main inclusion criteria is a history of recurrent acute pancreatitis (minimum of two confirmed pancreatitis attacks). The primary endpoint is time to acute pancreatitis recurrence after randomization. Secondary outcomes include changes in quality of life, gastrointestinal symptom scores, new-onset diabetes, exocrine pancreatic insufficiency, disease severity, health care utilization, adherence to treatment, and frequency of adverse events. Exploratory outcomes are included for mechanistic linkage and include the progression of chronic pancreatitis-related findings on magnetic resonance imaging (MRI) and changes in circulating blood markers of inflammation and fibrosis. DISCUSSION: This study investigates if naldemedine can change the natural course of pancreatitis in patients with recurrent acute pancreatitis and improve patient outcomes. TRIAL REGISTRATION: EudraCT no. 2021-000069-34. CLINICALTRIALS: gov NCT04966559. Registered on July 8, 2021.
引用
- Cook ME, Knoph CS, Fjelsted CA, et al. Effects of a peripherally acting µ-opioid receptor antagonist for the prevention of recurrent acute pancreatitis: study protocol for an investigator-initiated, randomized, placebo-controlled, double-blind clinical trial (PAMORA-RAP trial). Trials. 2023. PMID: 37127657. doi:10.1186/s13063-023-07287-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。